Kaplan Z, van Leeuwen N, van Klaveren D, Visser O, Posthuma E, van Lammeren-Venema D
BMJ Oncol. 2025; 3(1):e000264.
PMID: 39886140
PMC: 11234996.
DOI: 10.1136/bmjonc-2023-000264.
Al-Juhaishi T, Dela Cruz S, Gupta R, Keiffer G, Morrison V, Shapira I
Oncologist. 2024; 29(9):801-805.
PMID: 39159003
PMC: 11379644.
DOI: 10.1093/oncolo/oyae051.
Chen R, Cheng T, Xie S, Sun X, Chen M, Zhao S
Adv Sci (Weinh). 2024; 11(38):e2402332.
PMID: 39049685
PMC: 11481385.
DOI: 10.1002/advs.202402332.
Lin T, Liu D, Guan Z, Zhao X, Li S, Wang X
Heliyon. 2024; 10(8):e29382.
PMID: 38660246
PMC: 11040068.
DOI: 10.1016/j.heliyon.2024.e29382.
Hollands C, Boyd A, Zhao X, Reid J, Henly C, ElRafie A
Cell Rep Med. 2024; 5(4):101485.
PMID: 38582086
PMC: 11031376.
DOI: 10.1016/j.xcrm.2024.101485.
Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy.
de Camargo Magalhaes E, Hubner S, Brown B, Qiu Y, Kornblau S
Leukemia. 2024; 38(5):1046-1056.
PMID: 38531950
PMC: 11073970.
DOI: 10.1038/s41375-024-02208-8.
Spectrum of infections in different regimens of post-induction chemotherapy in acute myeloid leukemia (): A comparative retrospective study.
Majid H, Masoom M, Bansal N, Ahmad W, Khan M, Farooqui S
Heliyon. 2024; 10(3):e24561.
PMID: 38317981
PMC: 10839883.
DOI: 10.1016/j.heliyon.2024.e24561.
Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?.
Rahme R, Braun T
J Clin Med. 2024; 13(2).
PMID: 38256681
PMC: 10816428.
DOI: 10.3390/jcm13020549.
A Survival Analysis of Acute Myeloid Leukemia Patients Treated With Intensive Chemotherapy: A Single Center Experience.
Jimbu L, Valeanu M, Trifa A, Mesaros O, Bojan A, Dima D
Cureus. 2023; 15(8):e43794.
PMID: 37731446
PMC: 10508193.
DOI: 10.7759/cureus.43794.
TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal.
Li Y, Xue M, Deng X, Dong L, Truong Nguyen L, Ren L
Cell Stem Cell. 2023; 30(8):1072-1090.e10.
PMID: 37541212
PMC: 11166201.
DOI: 10.1016/j.stem.2023.07.001.
NLRP3 participates in the differentiation and apoptosis of PMA‑treated leukemia cells.
Wang Y, Xin C, Li X, Chang X, Jiang R
Mol Med Rep. 2023; 28(2).
PMID: 37350394
PMC: 10308454.
DOI: 10.3892/mmr.2023.13039.
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
Matthews A, Perl A, Luger S, Gill S, Lai C, Porter D
Am J Hematol. 2023; 98(8):1254-1264.
PMID: 37334852
PMC: 11057024.
DOI: 10.1002/ajh.26991.
Intravascular Complications of Central Venous Catheterization by Insertion Site in Acute Leukemia during Remission Induction Chemotherapy Phase: Lower Risk with Peripherally Inserted Catheters in a Single-Center Retrospective Study.
Picardi M, Giordano C, Pepa R, Pugliese N, Esposito M, Abagnale D
Cancers (Basel). 2023; 15(7).
PMID: 37046808
PMC: 10093126.
DOI: 10.3390/cancers15072147.
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity.
Bazinet A, Kadia T, Short N, Borthakur G, Wang S, Wang W
Blood Adv. 2023; 7(13):3284-3296.
PMID: 36884300
PMC: 10336257.
DOI: 10.1182/bloodadvances.2022009391.
Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question.
Jaramillo S, Schlenk R
Haematologica. 2023; 108(2):342-352.
PMID: 36722404
PMC: 9890037.
DOI: 10.3324/haematol.2022.280802.
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Niederwieser D, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali H
Ann Hematol. 2023; 102(3):547-561.
PMID: 36695874
PMC: 9977880.
DOI: 10.1007/s00277-023-05087-8.
Revisiting the outstanding questions in cancer nanomedicine with a future outlook.
Sudheesh M, Pavithran K, M S
Nanoscale Adv. 2022; 4(3):634-653.
PMID: 36131837
PMC: 9418065.
DOI: 10.1039/d1na00810b.
A tubulin binding molecule drives differentiation of acute myeloid leukemia cells.
Jackson T, Vuorinen A, Josa-Cullere L, Madden K, Conole D, Cogswell T
iScience. 2022; 25(8):104787.
PMID: 35992086
PMC: 9385704.
DOI: 10.1016/j.isci.2022.104787.
Single-cell genomics in AML: extending the frontiers of AML research.
Ediriwickrema A, Gentles A, Majeti R
Blood. 2022; 141(4):345-355.
PMID: 35926108
PMC: 10082362.
DOI: 10.1182/blood.2021014670.
Socioeconomic cost of AML in Sweden-A population-based study using multiple nation-wide registers.
Hernlund E, Redig J, Paulsson B, Rangert Derolf A, Hoglund M, Vertuani S
EJHaem. 2022; 2(3):385-393.
PMID: 35844713
PMC: 9176098.
DOI: 10.1002/jha2.208.
